Lexeo Gets FDA Fast-Track Designation for LX2006 in Friedreich's Ataxia Cardiomyopathy
By Colin Kellaher
Lexeo Therapeutics has won U.S. Food and Drug Administration fast-track designation for its LX2006 gene therapy candidate for the most common cause of death in people with a rare genetic neuromuscular disorder.
Lexeo on Tuesday said the designation covers LX2006 in the treatment of cardiomyopathy in patients with Friedreich's ataxia, an inherited disorder that causes progressive damage to the nervous system.
The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.
Lexeo, which previously won FDA rare-pediatric-disease and orphan-drug designations for LX2006 in the treatment of Friedreich's ataxia cardiomyopathy, said it is currently conducting a Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of the gene therapy.
The New York clinical-stage genetic-medicine company said there are currently no FDA-approved treatment options for Friedreich's ataxia cardiomyopathy.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 16, 2024 08:04 ET (12:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy
-
Snowflake Earnings: Mixed News, But Signs of Stability
-
Nvidia Earnings: AI Demand Smashes Expectations Again
-
After Earnings, Is Walmart Stock a Buy, a Sell, or Fairly Valued?
-
Target Earnings: Margins Hold Up, but Top Line Constrained by Weak Discretionary Spending